Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
12 hedge funds and large institutions have $741K invested in Hepion Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
140% more funds holding
Funds holding: 5 → 12 (+7)
84% more capital invested
Capital invested by funds: $403K → $741K (+$338K)
23% less call options, than puts
Call options by funds: $142K | Put options by funds: $184K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$205K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$118K |
| 3 |
Millennium Management
New York
|
+$104K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$71.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$97K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $189K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $178K | +$205K | +57 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $103K | +$118K | +33 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $63K | +$71.8K | +20 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $49K | +$57.4K | +16 | New |
|
6
Squarepoint
New York
| $48K | +$10.8K | +3 | +23% |
|
|
SFI
7
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| $48K | +$57.4K | +16 | New |
|
|
ECM
8
ExodusPoint Capital Management
New York
| $36K | +$43.1K | +12 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $14K | +$17.9K | +5 | New |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $8K | +$7.18K | +2 | +200% |
|
11
UBS Group
Zurich,
Switzerland
| $5K | +$7.18K | +2 | New |
|
|
12
Millennium Management
New York
| $91 | +$104K | +29 | New |
|
|
PFS
13
Prospera Financial Services
Dallas,
Texas
| – | -$97K | -34 | Closed |
|
|
14
Dimensional Fund Advisors
Austin,
Texas
| – | -$93K | -33 | Closed |
|
HEPA Hedge Fund Activity: Q3 2020 in Review
12 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2020, worth a combined $741K — up 84% from $403K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HEPA positions and 2 closed out — a net gain of 7 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $205K. The largest seller was Prospera Financial Services, exiting entirely with an estimated $97K sold.
- 12 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $741K of Hepion Pharmaceuticals stock for Q3 2020, up 84% quarter-over-quarter.
- 9 funds opened new Hepion Pharmaceuticals positions in Q3 2020 and 2 closed out, a net change of +7 holders.
- The largest Hepion Pharmaceuticals buyer in Q3 2020 was Sabby Management, an estimated $205K added.
- The largest Hepion Pharmaceuticals seller in Q3 2020 was Prospera Financial Services, an estimated $97K sold.
Based on aggregated 13F filings for Q3 2020.